AI To Be Used To identify Chronic Diseases Earlier – Theresa Says
Really!!! Have they any idea of implications for NHS – can they cope with the rush for treatment <<<AI>>
Really!!! Have they any idea of implications for NHS – can they cope with the rush for treatment <<<AI>>
Fairly logical really but certainly a 40,000 patient study would give weight to the conclusions!!! Also adds weight to the use of AChEs for the symptomatic relief of cognitive symptoms in confirmed AD patients <<<AntiCholinergics>>>
HoL picked up on basic deficiency in this strategy then Give it to the NHS but don’t tell them 🙂 <<<NHS>>>
Interesting article from Cytel Fairly obvious really – Some really simple rules! -Only select few really good sites (50% don’t recruit) -Don’t make protocol too extensive and complicated (don’t want amendments) -Collect only essential info not nice to have -Don’t do adaptive designs! <<Part 1>> <<Part 2>>
For too long AD have been a too highly variable environment for clinical research! -The patients present with highly variable conditions -The treatments have widely different modes of action and possible targets -The assessment measures are highly variable and subject to large errors No wonder it has been almost impossible to pick up any indicators […]
Subjects with 2 ApoE4 genes are 12 times more likely to get AD than those with the normal gene (ApoE3) So although scientists know that amyloid protein breakdown is important in the disease therapeutics targetting these proteins has been one long list of failures This is a very interesting potential explanation – neurons produced from […]
First it was Lilly then Pfizer then Axovant then Merck and almost Biogen/Eisai and now vTV (whoever they are) But then it was only 2 lots of 400 patients and the ADAS and CDR – what did they expect! <<<ALZ>>>
Very interesting stuff from Pharma Times Distributed security applied to patient health records right through to drug supply <<<BLOCKCHAIN>>>
Doesn’t look like Statisticians will be running out of things to do any time soon 🙂 <<<REAL WORLD>>>
I’m sure we did some sample size calcs for Michalis sometime ago <<<BRAINOMIX>>
I thought combined therapy was already approved Worth trying anything once the AD symptoms appear! Even though I’ve never been convinced about memantine <<<MEMANTINE>>>
This article refers to the high placebo response rate (50%) in MDO specifically but equally appplies to all therapeutic areas >>> >>>GET RECRUITMENT RIGHT -True MDO patients -True assessment by clinicians to select right subjects (keen to influence score on in/ex) -Personnel lack of understanding of AIM = to test null hypothesis /estimate treatment effect […]
This is going to be huge These companies have access to vast EHR databases and this will speed access to doctors, to patients and to records! <<<BLOCKCHAIN>>>
What a brilliant idea! Blocks of information linked by unique identifiers to the input (node) and output (next block) – So any change to it invalidates the block No central authority (‘middle man’) and no corruption Model: Nodes/Transactions/Data/Logic First off – individual patient medical health records – self retained and encrypted! Second – Regulatory bodies […]
Using historical data to predict future population actions – epidemics to genocide! Not something that’s too far off reality <<<BIG DATA>>>
I’m not so sure more or everything is a good thing –Â Typical ‘greedy’ human state though! Brain implants to improve learning, memory, communication (brain to brain) or heighten sensation! <<<COGNITION>>>
A large proportion (84%) of NHS hospitals apparently still don’t declare finances received from drug companies Isn’t this a violation of the ABPI code of practice? I don’t see what the problem is BOTH Investigators (and Patients!) should be paid for work performed in clinical development BUT it all should be in the open and […]
Anitbodies to amyloid plaques – now haven’t we heard that before somewhere? Hasn’t worked yet – because the neuronal damage is already done and empyting the ‘dustbin’ won’t help! <<<PLAQUES>>>
Electronic health records made publicly available for research Netanyahu obviously reckons they can may ‘big money’ from it! <<BIG DATA>>>
AI and Big Data words are ‘all the rage’ Companies are making a fortune and raising millions in VC funding claiming to do something very new and fancy! All they’re doing is repurposing compounds based on ‘mining’ existing data >> Atomwise/Benevolant/Twoxar/Numedii To do it they’re just using graphical analytics to look for patterns and trends or […]
In an elderly population 54% preferred CBT – since when was that ‘MOST’ And surprise surprise CANTAB provide a computer based battery !!!! What I did like though – was that most subjects preferred testing at home! <<<TESTING>>
Big news announcement today NIH to get $414m for Alzheimer’s Research to take total to $1.8bn!!! <<<FUNDING>>>
Very interesting stuff and major potential for IBS maybe? <<<GUT MONITORING>>>
Looks like Celgene are risking $100 upfront to partner with Prothena’s (Irish Biotech) Tau antibody programme Tau targets are the latest alternative to amyloid They are however ‘edging their bets’ by also putting $100 into Vividion programme to develop new small molecule treatments <<<Celgene>>>
Is this why Amazon are getting involved? 🙂 <<<Amazon>>>
Precordia company from Turku University have come up with great idea Using accelerometers in smartphones to detect abnormal heart rhythms Then analysing it to predict stroke. blood clots and heart failure <<<ECG>>>
Do you really want to be messing with vital hormones!!! Testosterone lowering is not a good idea in my book They have no idea of the long term effects or what else they potentially impair like growth and cell repair <<<TESTOSTERONE>>>
Interestingly they reckon not due to ageing, flu or cold weather but might be up turn in cancelled operations Would be an interesting modelling project 🙂 <<<MORTALITY>>>
All very topical given the last weekends activities in our little own hometown – Salisbury! Looks like these nerve toxins like Sarin and Vx are just pumped up versions of the Acetylcholine esterase inhibitors we use for Alzheimers! They like our old friend galantamine (we did all the early development work) just block the breakdown […]
Nicely put – rather have the patient ‘shop’ at the clinic take the ‘shop’ on line to the patient 🙂 Ok if the condition your treating allows for home assessment and you can validate ‘real life’ data But always useful for follow ups <<<AMAZON>>>
Think we’ve heard this story a thousand time before and every Global pharma Phase III trial has failed with it! I thought they’d realised that targeting AB protein had a basic flaw – that is that some people have amyloid plaques but no AD! >>>Immunological Target<<<
Goedert, De Strooper, Hardy and Haas – leaders in neurological research! I like Hardy’s comment about current treatments being prescribed too late after the onset of the disease It’s unlikely we’ll find a revolutionary treatment but hopefully we’ll make small steps in to slowing the disease in the next few years <<BRAIN>>
Very interesting approach and very topical given major cancers with Opioid addiction and abuse (eg: suboxone) Rather than targeting brain sensation target molecular pathway sending message to brain through protein Opens possibility to whole range of treatments for different pain related illnesses >>>PAIN<<<
Not everything they do is aimed at rare disease <<<Constipation>>
I’ve been waiting for something like this for sometime Gives the CRO/Phar,ma more control over patient recruitment Can’t be bad! >>> <<Recruitment>>>
Interesting idea and maybe better than some of the devices we’ve been working on 🙂 Not sure I trust Russians though at the moment <<Hemostasis>>
Skydio – a drone which follows your every movement. Very cool but I’m not sure I can justify using it in our Clinical Trials anywhere – pity 🙂 Watch the vid! <<<Skydio R1>>
A hot topic with suboxone at the moment Not sure how Adapax (benzhydrocodone and acetaminophen) from Kempharm differentiates itself – especially as still ‘high potential for abuse’ Its just a combination of a couple of old drugs and ‘KemPharm hoping to differentiate its product once it hits the market’ sounds vague But basically its $150m […]
Six biologics to be fast tracked from MedImmune (AZ owned) through a separate company – Viela Bio Inflammatory and auto-immune (incl neuromyelitis) – all rare diseases They’ll make a fortune! All because outside AZ core >>> oncology, respiratory and cardiovascular and metabolic disease (seems pretty broad to me!) J&J situation with Actelion buyout where […]
Now this really could be huge Lifetime data from millions – a statisticians dream! Trouble is the brits have a reputation for giving away crown jewels – penicillin – jet engine – internet! John Bell is absolutely right! We need to make sure this doesn’t end up in California! <<BIG DATA>>>
I didn’t know there were 5 – Type IIs Auto-immune / Insulin deficient / Insulin resistant / Obesity related / Age related With Obesity and Age making up 60%! <<Diabetes>>
Very clever of Rock Health – emphasise benefit on an individual basis Sometimes we forget when dealing with the ‘whole’ package <<DIGITAL STORIES>>>
Is this a Marketeers dream or what! Maybe even an Smartphone app 🙂 <<<DEPRESSION>>>
Now this is a very simple idea and a very clever way of extending the use of vaccines No wonder Prokarium have the funding for Vaxonella <<<Vaccines>>>
I’m not surprised they’re reticent! Look up Collins paper in Nature a few weeks ago – brilliant stats assessment of IP-Mass Spec to measure amyloid in PET scans and CSF samples And it’s a very accuratealternative to CSF sampling I do wonder if it’s commercially viable thought (I don’t know enough about IP-MS) <<<AD Risk […]
Thank god for Statisticians – I hate it when clinicians refer to single cases At least there is a big follow up survey And this isn’t rocket science either! <<<DIET>>>
Now this is fascinating – Apple trying to match medical records with subjects on smartphones Would this mean we could do the ultimate in virtual trials Recruit patients from iPhone database, import history data, order and provide medication electronically, prompt patients to take meds and to record ePRO data and even record automically vital signs. […]
I know we’re in the business of making and selling drugs to patients but this is worrying Rosanna O’Connor’s, Public Health England, review will be interesting <<<Hooked>>>
This time it’s Takeda’s turn with pioglitazone (repurposing diabetic treatment) in Phase III <<<AD Failure>>>
Interestingly researchers think the brain potential rewiring may just be turned off with age Valproate an epilepsy drug might help in stroke >>>STROKE<<<
Has your data had this sort of non normal distribution look (as in depression example) Worth considering Robust regression and Bootstrapping and not just ignoring outliers 🙂 <<<NEW METHODS>>>
Just shows you the value of ‘weight of evidence’ ie numbers of subjects >>>Depression Meta Analysis<<<
By popular demand we will restart the blog commenting on interesting daily news items We’ll start with a bit of a catch up – posting interesting items from the last few months 🙂
Now this is what I call a useful app 🙂 <<<Ultrasound>>>
Never did like Medidata products but this one will have Bradford Hill turning in his grave! <<<TheTIMES>>>
Another antibody targeting Tau protein for the treatment of AD! <<LINK>>
Obviously these guys aren’t sportsmen! Just showing you can extend endurance doesn’t improve fitness We had a soluble glucuronic acid did the same thing Preferentially burning fat may be useful treatment in obesity <<<LINK>>>
Bryostatin’s mechanism of action is to modulate protein kinase activity  (pka) and reduces amyloid and tau apparently Still doesn’t work >>> LINK<<<
If this isn’t the most amazing use of a Smartphone I don’t know what is!!! >>>LINK<<<
I really don’t get this! What about all the other confounding factors??? >>> LINK <<<
Now this is what I call a ‘usable’ device for collecting lifestyle data away from the clinic. No interfering from the patient! <<<LINK>>
I really like the MC10 Biostamp Looks like all the mobile data (from motion sensors) here is being used in our gaydar plots 🙂 >>>LINK<<<
If there’s anything novel about your programme? Then it’s a no brainer !!! >>> <<LINK>>>
It’s about time the government (NICE) tightened up on Pharma pricing of drugs! >>LINK<<
Really! Pharma intends to get voice enabled computers to remind patients about nutrition plans and dosing at least initially in Type II diabetes >>> <<LINK>>
Freezing organs for donors is fine The problem comes when trying to reheat them for use! Using silica-coated iron oxide nanoparticles as part of the freezing process is a very neat way of solving the warming problem and helping organs to last longer in the deep freeze >>> <<LINK>>Â
Takeda using the iWatch to collect ‘real life’ data from Parkinson’s patients Including continuous vitals monitoring with prompted cognition and mood data in ePRO form >>> http://www.fiercepharma.com/marketing/takeda-partners-cognition-kit-wearable-study-for-depression?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiWXpka05qVTBaRGxrWm1abCIsInQiOiJpSmVueXM1RDBYRHRGVklGeVBscThBYzRFVG1uZGgrT2F3UXBycjR3ZmFKSHJLeVA5QWJGbFo0WUFNQzZyenJKVzJhZ3lOdXIwK1ppXC9yNnZJYXV2MDkrenJqM0g0d1E2blBvS0ZDeTlXUkc3ZjJDS2gwd3k2RVRCcmczMFFMRXMifQ%3D%3D
Another use for stem cell technology I did talk to Aidan Courtney at Censobio.com who expects to do a similar thing – predicting response to AD treatment with stem cell testing>>> http://newatlas.com/stem-cells-personalized-testing-cancer-drug/48178/?utm_source=Gizmag+Subscribers&utm_campaign=08c7982cf2-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-08c7982cf2-91677545
AC Immune’s crenezumab already has one Phase III trial in progress now they’ve started another. All based on their ‘failed’ Phase II study. Where’s the sense – or is it just me >> http://www.fiercebiotech.com/r-d/roche-starts-second-alzheimer-s-phase-3-anti-abeta-drug?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTkdJMFpUZzFaakkwTmpBeCIsInQiOiJoVWxqQ2tsbFVjSjlWSThTK3pZM2lHTFY0TTI3NGVSamFqUjRINnVCdzlZdkM0S0RwODBzU0hleTZmckg4QjcyaEFwSVhSOHd3XC9xUnZ5TWNGTzZweWordllsZU9EZ2pOVWVSSHRLNnJqTWpEekl4eWkweHpEejN2Y2xEcTlVYzIifQ%3D%3D
Did they really think this was going to work in the first place A triglyceride and a re-formulation with less bioavailability post Phase II Who funds these ideas! >> More Phase 3 disappointment in Alzheimer’s disease
Apparently the MHRA is may consider developing links with the FDA post Brexit now the the EMA will move out of London The aim would be to have agreement in place to allow fast track approvals. Now that would be interesting >>> http://www.thetimes.co.uk/edition/business/britain-eyes-american-drug-approval-pact-0mwrj7g6f
Looks like they want to use NExT to interrogate medical records in a big way>>>> Microsoft refocuses in healthcare, teams with UPMC on innovation
How about Transhumanism for the ultimate connection to technology >> http://newatlas.com/transhumanism-mainstream-era-popular/47941/?utm_source=Gizmag+Subscribers&utm_campaign=451d4e2031-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-451d4e2031-91677545
Keith’s CogTrack finds some interesting effects on short/long term memory and speed of retrieval >>> Study: Red Bull energy drink boosts memory performance
This time Merck’s BACE inhibitor of amyloid beta >> http://www.pharmatimes.com/news/merck_pulls_plug_on_late-stage_alzheimers_trial_1186737?utm_source=PT+Daily+Newsletter&utm_medium=email&utm_campaign=pt+daily+news+alert
Apparently 11 patients treated is sufficient now for developers to go straight into a big Phase III trials Sounds like Lilly all over again! Whatever happened to classic drug development? Obviously the review article I did with Bengt Winblad and Julian Gray didn’t put any one off >> http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTTJRNE1UQTNNV1prWVdRMCIsInQiOiI3UlpZdEFXMTRldkIySSt3WFQyaitKVGl2YkNENWRNY0V1eUtESjJ5ellmQVVmaURvWXNIbmppYmxjSmZUczA3TkwxejRZMnpvSmlXdTExZk1aYUFIWG1JM1RTT0d4ZGpaR0dGckVybVdMQTgrWDc0VFdBN0ZcLzdrcllkSlh3UjgifQ%3D%3D
Very interesting new press release No idea why the Intercept share price went down given that it’ll be much easier now to get a positive trial result with statistical significance on only one or other of the co-primary endpoints and it’s reduced the number of subjects required in total as well! It certainly does raise […]
Fascinating stuff from Stanford using electrophoresis in a microfluidic chamber to diagnose diseases And affordable >>> http://newatlas.com/stanford-microfluidic-lab-on-a-chip/47775/?utm_source=Gizmag+Subscribers&utm_campaign=a8bafb40ef-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-a8bafb40ef-91677545
Lundbeck’s 5-HT6 antafonist (idalopirdine ) has failed in 3 attempts >>> http://www.fiercebiotech.com/biotech/lundbeck-calls-time-alzheimer-s-drug-after-more-failure?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTkdNNU1UZGxNR05pTjJJeiIsInQiOiJxWnhDQTcySXZCQm1MeTE4THZXWEVnTlZGa1JNMVRVOVNmVFFCUHZTWjJrZkRBdjJPY2Zxd0l0aVdOOEZaMVwvWFdSNUI0dlNaaFArWWd2eVNNUGJndllOVDZKdjZ2ZUREdmQyWDIzcTdmOFRtMHpuYmp1QUpSYUxObU9mSmo2NXQifQ%3D%3D
Bioelectric systems Sensing the environment and triggering response through electrochemical response Disease/Illness detection and treatment ‘all in one’!!! >>>> http://newatlas.com/cyborg-technology-scientists-create-bioelectric-hybrid-cells/47481/?utm_source=Gizmag+Subscribers&utm_campaign=69a7338016-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-69a7338016-91677545
News items in the Times over the last 2 days. Seems like the disease is still winning for all our efforts >>> http://www.thetimes.co.uk/past-six-days/2017-01-30/news/drug-failure-deals-blow-to-dementia-sufferers-ll27jd65r http://www.thetimes.co.uk/edition/news/century-long-war-on-alzheimers-edges-towards-uncertain-endgame-n9mm9k0jk
The benefits of microdosing LSD, although cognition wasn’t specifically mentioned>>>> http://newatlas.com/lsd-long-trip/47551/?utm_source=Gizmag+Subscribers&utm_campaign=2a58092796-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-2a58092796-91677545
Another Phase II with an Anit-Tau antibody (AbbVie) Does this bode well for the ‘front runner’ Axon especially after TauRx fell at the first? And what about the others in the pack at the back: Eisai/Biogen, Bristol-Myers Squibb and Astellas? >>>> eyJpIjoiWWprNU56UmhPR1ppT1RFeCIsInQiOiJxTTlsOWcxaWZkU3YwVmF2TFFYOUhNTVg1eDJpTVVPWGRVUGN4cXdFSjlLMzcyM2J6Tld0OWc2OEpjekE2MGdBeVJORmFWelZ5Sk5yNkdadSs1VkhKajMwYjRBSGthdHlFbHVFRGh6UWo5aHdyNjJLclY1NnpPb0RlQ25GWjdVRCJ9
Not a formal survey but this poll shows what concerns there are for clinical trials Complexity / Regulations / Costs / Patient access / Staff? / Technology / Oversight / New drugs Bring it on! 🙂 >>> http://www.clinicaltrialpartnershipsblog.com/2016/11/report-8-biggest-challenges-facing.html?utm_source=PCT+Blog+Registrations&utm_campaign=8ce0a92a2a-PCT_Content12_bloglist_top5_04_01_17&utm_medium=email&utm_term=0_81d996f2c9-8ce0a92a2a-132135521&goal=0_81d996f2c9-8ce0a92a2a-132135521
‘Digital health’ tools to support clinical trial conduct – including management and monitoring Link it all together with ‘mHealth’ – patient retention/questionnaires through apps and sensors in wearable tech- to get the ultimate clinical trial? >>> http://www.clinicaltrialpartnershipsblog.com/2016/09/clinical-trials-and-iot-how-mhealth.html?utm_source=PCT+Blog+Registrations&utm_campaign=8ce0a92a2a-PCT_Content12_bloglist_top5_04_01_17&utm_medium=email&utm_term=0_81d996f2c9-8ce0a92a2a-132135521&goal=0_81d996f2c9-8ce0a92a2a-132135521
Interesting thoughts from Exco (some good some not so good)!!! -Break with tradition and adopt new technology -Make patients the centre of the trial -Collect data seamlessly (no human involvement and therefore validation issues) -Use patients own devices I just hope they don’t forget the primary objective of any trial is to assess the efficacy […]
And you wonder why pharma have a bad name Some of these companies you might expect but not Pfizer They were very sneaky selling to Flynn and getting them to increase the price of phenytoin for epilepsy by 2600% ! I bet the £84m fine didn’t hurt too much! >>>> http://www.thetimes.co.uk/article/duplicate-permits-let-manufacturers-keep-their-dominance-fsrkp3lnq?shareToken=fdb66b66afe630645809670d8992a145
Humans are a lazy species anyway – this should make us worse!!! >>> http://www.thetimes.co.uk/article/facebook-boss-wants-service-with-ai-smile-dst9g3gzw?shareToken=3c96790ec26b35178b4e275351639357
More close relations to help developers of diagnostic tests and medical devices apparently! >>> http://www.pharmatimes.com/news/nice_links_with_fda_to_accelerate_access_to_med_tech_1182083
But this one is novel – wearable tech Flickering light stimulation! >>>> Non-invasive visual stimulation to treat Alzheimer’s disease
M1 muscarinic receptor proteins for the improvement for cognition have been used before. One without serious side effects would be interesting 🙂 >>>>
Apparently graphene molecules are very sensitive and cancer cells modify charge at its surface. The change in atomic vibration is then detected. Wow whatever next for graphene! >>> http://newatlas.com/graphene-cancer-detection/47044/?utm_source=Gizmag+Subscribers&utm_campaign=69b4aefc4e-UA-2235360-4&utm_medium=email&utm_term=0_65b67362bd-69b4aefc4e-91677545
As an injection as well! >>> http://www.fiercepharma.com/marketing/allergan-eyes-depression-as-blockbuster-botox-next-big-stage?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTVRKbU0yVmlOakV6WlRNMyIsInQiOiI1UytxY3FlVmd6cWcwSldsbHptMTFHUFV3R1hlQTd3ZVBtNExXY2dSYWF2SnhCb0dOUlk2NGJtSlA4MENXMFg2eCtITm40Qzd4WGltK3c0Y2FPR2tjYmdvb3FDdmVpZWNRNDZTSXRSQlRxQTBseDZCVHczUmlHUlwvbkQrcVFQK3QifQ%3D%3D